Dyadic Secures $3.1M Gates Grant; C1 Platform Achieves 15-Day Protein Production
DYAI•Dyadic International received the final $738,743 payment of a $3.1 million Gates Foundation grant for RSV and malaria monoclonal antibody programs, with C1 demonstrating yields and neutralization comparable to CHO systems. In a $4.5 million CEPI/FBS collaboration, C1 achieved plasmid-to-protein production in about 15 days.
1. Gates-Funded Monoclonal Antibody Progress
Dyadic’s C1 platform received a full $3.1 million grant from the Gates Foundation, including a final $738,743 payment in June 2026, to support RSV and malaria monoclonal antibody research. Early studies indicate C1-produced antibodies match CHO cell systems in binding and neutralization while delivering higher yields at lower projected costs.
2. CEPI/FBS Collaboration Accelerates Production
Under a $4.5 million collaboration with CEPI and Fondazione Biotecnopolo di Siena, Dyadic demonstrated plasmid-to-purified-protein production in approximately 15 days using C1. This rapid timeline highlights the platform’s potential to shorten development cycles for vaccine antigens and therapeutic antibodies.
3. Scripps Ebola Antigen Delivery
In partnership with Scripps Research, Dyadic is applying its C1 workflow to produce Bundibugyo Ebola antigens, with initial purified samples slated for delivery by the end of July 2026. This collaboration aims to showcase C1’s ability to support accelerated outbreak response efforts.
4. Market Opportunity and Commercial Strategy
The global biologics market exceeds $690 billion and is projected to surpass $1.3 trillion by 2033, with an addressable opportunity of more than $25 billion in biologics manufacturing, recombinant proteins, vaccines and enzymes. Dyadic’s commercialization strategy includes partner-funded programs, manufacturing collaborations, licensing, royalties and broader market adoption.
